Clinical Trial

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-26; most recent amendment 2026-06-11.
Status change: Not Yet Recruiting → Recruiting 2023-07-05
Trial Details
NCT Number NCT05892393
Lead Sponsor Robert Flavell, MD, PhD
Collaborators: National Cancer Institute (NCI)
Conditions Multiple Myeloma, Plasma Cell Myeloma
Enrollment 20 participants
Start Date 2023-06-16
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15